Skip to content

Study · Observational study · n = 307 · 2018

11 results

Liraglutide and cardiovascular outcomes in a real world type 2 diabetes cohort.

Mirani M, Favacchio G, Serone E, Lucisano G, Rossi MC, Berra CC

Pharmacological research10 Sept 2018Cited by 20 (Europe PMC)

PMID30213563 (opens in a new tab)DOI10.1016/j.phrs.2018.09.003 (opens in a new tab)PepBankPUB-30213563
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes in routine care, HbA1c fell by 1.0% over 36 months of liraglutide treatment.

    In plain wordsIn adults with type 2 diabetes in routine care, HbA1c was lower after 36 months of liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change
    Study

    n = 307

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 36 monthsAs given in this study (human).

    Measurements

    HbA1c change
    −1%
    36 months

    Source sentences

    Summary
    Improvements during 36 months were found in HbA1c (-1.0%; p < 0.0001)
    1 context sentence
    Summary · context
    We conducted an observational, retrospective, longitudinal study based on 307 patients with T2DM treated with liraglutide under routine clinical practice conditions.
  2. 02HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes in routine care, fasting blood glucose fell by 17.6 mg/dL over 36 months of liraglutide treatment.

    In plain wordsIn adults with type 2 diabetes in routine care, fasting blood sugar was lower after 36 months of liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting blood glucose change
    Study

    n = 307

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 36 monthsAs given in this study (human).

    Measurements

    Fasting blood glucose change
    −17.6 mg/dL
    36 months

    Source sentences

    Summary
    fasting blood glucose (-17.6 mg/dL; p < 0.0001)
    1 context sentence
    Summary · context
    We conducted an observational, retrospective, longitudinal study based on 307 patients with T2DM treated with liraglutide under routine clinical practice conditions.
  3. 03HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes in routine care, body weight fell by 3.2 kg over 36 months of liraglutide treatment.

    In plain wordsIn adults with type 2 diabetes in routine care, body weight was lower after 36 months of liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change
    Study

    n = 307

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 36 monthsAs given in this study (human).

    Measurements

    Body weight change
    −3.2 kg
    36 months

    Source sentences

    Summary
    body weight (-3.2 kg; p < 0.0001)
    1 context sentence
    Summary · context
    We conducted an observational, retrospective, longitudinal study based on 307 patients with T2DM treated with liraglutide under routine clinical practice conditions.
  4. 04HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes in routine care, waist circumference fell by 1.45 cm over 36 months of liraglutide treatment.

    In plain wordsIn adults with type 2 diabetes in routine care, waist size was smaller after 36 months of liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseWaist circumference change
    Study

    n = 307

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 36 monthsAs given in this study (human).

    Measurements

    Waist circumference change
    −1.45 cm
    36 months

    Source sentences

    Summary
    waist circumference (-1.45 cm; p = 0.004)
    1 context sentence
    Summary · context
    We conducted an observational, retrospective, longitudinal study based on 307 patients with T2DM treated with liraglutide under routine clinical practice conditions.
  5. 05HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes in routine care, systolic blood pressure fell by 10.41 mmHg over 36 months of liraglutide treatment.

    In plain wordsIn adults with type 2 diabetes in routine care, the upper blood pressure number was lower after 36 months of liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseSystolic blood pressure change
    Study

    n = 307

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · 36 monthsAs given in this study (human).

    Measurements

    Systolic blood pressure change
    −10.41 mmHg
    36 months

    Source sentences

    Summary
    systolic blood pressure (-10.41 mmHg; p < 0.0001)
    1 context sentence
    Summary · context
    We conducted an observational, retrospective, longitudinal study based on 307 patients with T2DM treated with liraglutide under routine clinical practice conditions.
  6. 06HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes in routine care, diastolic blood pressure fell by 3.69 mmHg over 36 months of liraglutide treatment.

    In plain wordsIn adults with type 2 diabetes in routine care, the lower blood pressure number was lower after 36 months of liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseDiastolic blood pressure change
    Study

    n = 307

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · 36 monthsAs given in this study (human).

    Measurements

    Diastolic blood pressure change
    −3.69 mmHg
    36 months

    Source sentences

    Summary
    diastolic blood pressure (-3.69 mmHg; p < 0.0001)
    1 context sentence
    Summary · context
    We conducted an observational, retrospective, longitudinal study based on 307 patients with T2DM treated with liraglutide under routine clinical practice conditions.
  7. 07HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes in routine care, total cholesterol fell by 7.96 mg/dL over 36 months of liraglutide treatment.

    In plain wordsIn adults with type 2 diabetes in routine care, total cholesterol was lower after 36 months of liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseTotal cholesterol change
    Study

    n = 307

    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated · 36 monthsAs given in this study (human).

    Measurements

    Total cholesterol change
    −7.96 mg/dL
    36 months

    Source sentences

    Summary
    total cholesterol (-7.96 mg/dL; p =0.008)
    1 context sentence
    Summary · context
    We conducted an observational, retrospective, longitudinal study based on 307 patients with T2DM treated with liraglutide under routine clinical practice conditions.
  8. 08HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes in routine care, triglycerides fell by 20.60 mg/dl over 36 months of liraglutide treatment.

    In plain wordsIn adults with type 2 diabetes in routine care, triglycerides were lower after 36 months of liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseTriglyceride change
    Study

    n = 307

    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated · 36 monthsAs given in this study (human).

    Measurements

    Triglyceride change
    −20.6 mg/dl
    36 months

    Source sentences

    Summary
    triglycerides (-20.60 mg/dl; p = 0.01).
    1 context sentence
    Summary · context
    We conducted an observational, retrospective, longitudinal study based on 307 patients with T2DM treated with liraglutide under routine clinical practice conditions.
  9. 09HumanObservational studySafety outcome

    In adults with type 2 diabetes in routine care, no severe hypoglycemia occurred during liraglutide treatment.

    In plain wordsIn adults with type 2 diabetes in routine care, no severe low blood sugar events occurred on liraglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeSevere hypoglycemia
    Study

    n = 307

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · 36 monthsAs given in this study (human).

    Source sentences

    Summary
    No severe hypoglycemia occurred.
    1 context sentence
    Summary · context
    We conducted an observational, retrospective, longitudinal study based on 307 patients with T2DM treated with liraglutide under routine clinical practice conditions.
  10. 10HumanObservational studySafety outcome

    In adults with type 2 diabetes in routine care, major cardiovascular events occurred at 2.59 per 100 person-years, lower than the 3.4 reported in the LEADER study.

    In plain wordsIn adults with type 2 diabetes in routine care taking liraglutide, heart and stroke events were less frequent than in the LEADER trial.

    Peptide
    Liraglutide
    Outcome
    Not applicableMajor adverse cardiovascular event incidence
    Study

    n = 307

    Comparator
    LEADER study
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · 36 monthsAs given in this study (human).

    Measurements

    MACE incidence
    2.59 events per 100 person-years
    this cohort
    MACE incidence
    3.4 events per 100 person-years
    LEADER

    Source sentences

    Summary
    Incidence of MACEs in this cohort was lower than in the LEADER study (2.59 vs. 3.4 events per 100 person-years), confirming CV safety of liraglutide even in the real world.
    1 context sentence
    Summary · context
    We conducted an observational, retrospective, longitudinal study based on 307 patients with T2DM treated with liraglutide under routine clinical practice conditions.
  11. 11HumanObservational studySafety outcome

    In adults with type 2 diabetes and established cardiovascular disease taking liraglutide, cardiovascular events occurred at 8.1 per 100 person-years.

    In plain wordsIn adults with type 2 diabetes and established cardiovascular disease, cardiovascular events still occurred at 8.1 per 100 person-years despite liraglutide.

    Peptide
    Liraglutide
    Outcome
    Not applicableCardiovascular event incidence in established cardiovascular disease
    Study

    n = 307

    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · 36 monthsAs given in this study (human).

    Measurements

    CV event incidence
    8.1 events per 100 person-years
    established CV disease

    Source sentences

    Summary
    On the other hand, a higher incidence of CV event in patients with established CV disease was documented (8.1 events per 100 person-years), in spite of the use of liraglutide.
    1 context sentence
    Summary · context
    We conducted an observational, retrospective, longitudinal study based on 307 patients with T2DM treated with liraglutide under routine clinical practice conditions.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.